Sumatriptan News
POZEN Submits Full Response to FDA Approvable Letter For Trexima(TM)
POZEN Inc. today announced the submission of the full response to the Approvable Letter for Trexima(TM), the proposed brand name for the combination of sumatriptan succinate, formulated with RT Technology(TM), and naproxen...
Is Dr. Reddy's Playing It Smart? Or Is It Glaxo?
India’s leading Para IV challenger – Dr. Reddy’s Laboratories (DRL) has finally zeroed down to settle its pending Para IV patent litigation with GlaxoSmithKline (GSK) over the blockbuster anti-migraine drug, Imitrex, generically...
Dr. Reddy’s Announces Settlement of Imitrex® Litigation with GlaxoSmithKline
Dr. Reddy’s Laboratories announced today that it has settled patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, the generic version of GlaxoSmithKline’s Imitrex® tablets.
Pozen, Inc. (POZN) And GlaxoSmithKline (GSK) Report Receipt Of Approvable Letter For Investigational Migraine Treatment; FDA Requests Additional Safety Information
Pozen, Inc. (POZN) And GlaxoSmithKline (GSK) Report Receipt Of Approvable Letter For Investigational Migraine Treatment; FDA Requests Additional Safety Information
Hercules Technology Provides $10.0 Million Financing To TransOral Pharmaceuticals, Inc., A Specialty Pharmaceutical Company Developing Products For The Treatment Of Insomnia And Migraine
Hercules Technology Growth Capital, Inc. , a leading specialty finance company providing venture capital and private equity backed technology and life science companies with debt and equity growth capital, announced that on May...